Published in Wien Med Wochenschr on May 09, 2013
A case report of severe calciphylaxis - suggested approach for diagnosis and treatment. BMC Nephrol (2017) 0.75
Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med (1999) 15.69
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2009) 12.66
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med (2012) 8.88
Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant (2003) 6.15
Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2006) 5.69
Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int (2000) 3.29
Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med (1989) 2.40
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int (2010) 2.31
Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol (2004) 2.10
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ (1995) 2.10
Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol (2010) 2.06
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl (2003) 2.04
Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev (2007) 1.88
A novel mechanism for skeletal resistance in uremia. Kidney Int (2000) 1.88
Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol (2011) 1.84
Risk of hip fracture among dialysis and renal transplant recipients. JAMA (2002) 1.81
Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int (2006) 1.75
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int (2005) 1.64
Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res (2006) 1.63
Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol (2008) 1.62
Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis (2007) 1.58
Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis (2004) 1.54
Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol (2003) 1.48
Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med (1991) 1.42
19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol (1998) 1.34
Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int (1994) 1.28
Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis (2007) 1.27
Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol (2008) 1.25
An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol (2008) 1.22
Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant (1996) 1.21
Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab (1988) 1.11
Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol (2011) 1.04
Heterogeneity of the skeleton: comparison of the trabecular microarchitecture of the spine, the iliac crest, the femur, and the calcaneus. J Bone Miner Res (1996) 1.04
Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis (1995) 1.03
Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol (2001) 1.03
Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol (2001) 1.02
Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol (2000) 1.00
Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol (2002) 1.00
Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis (1996) 0.97
Can DXA predict fractures in renal transplant patients? Am J Transplant (2008) 0.95
A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation (2005) 0.95
Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation (1994) 0.94
Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant (1995) 0.94
Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study. Kidney Blood Press Res (2010) 0.94
Effect of kidney transplantation on bone. Eur J Clin Invest (2006) 0.93
Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int (2000) 0.93
Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int (1984) 0.91
Changes in bone mass early after kidney transplantation. J Bone Miner Res (1994) 0.89
Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int (2003) 0.89
Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc (2007) 0.87
Studies of bone morphology, bone densitometry and laboratory data in patients on maintenance hemodialysis treatment. Nephron (1985) 0.87
The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients. Clin Nephrol (2009) 0.86
Aortic calcification contributing to bone densitometry measurement. J Clin Densitom (1999) 0.85
Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplant Proc (2000) 0.85
Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. J Bone Miner Res (1986) 0.83
The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transplant (2010) 0.81
Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int (1999) 0.81
Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis (2002) 0.80
The exchangeable calcium pool: physiology and pathophysiology in chronic kidney disease. Nephrol Dial Transplant (2011) 0.80
Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol (2003) 0.79
A prospective randomized study for the treatment of bone loss with vitamin d during kidney transplantation in children and adolescents. Am J Transplant (2004) 0.78
Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis (2000) 0.78
Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc (2002) 0.77
Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol (1986) 0.77
Procollagen type I C-terminal extension peptide in predialysis chronic renal failure. Am J Nephrol (1992) 0.77
Early therapy of renal bone disease with calcitriol: a prospective double-blind study. Kidney Int Suppl (1989) 0.77
Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis (2002) 0.76
Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant (2004) 0.76
Bone histologic response to deferoxamine in aluminum-related bone disease. Kidney Int (1987) 0.76
Serum calcium, phosphate and alkaline phosphatase and morphometric bone examinations in 30 patients with renal insufficiency. Calcif Tissue Res (1974) 0.75